David Foster

ANOTHER PATENT ISSUED for BIOELECTRIC STIMULATOR https://lnkd.in/g2cCCnkq for organ regeneration including skin and hair, healing including joint health and healthspan extension October 8th, 2014 by the USPTO! https://lnkd.in/g2cCCnkq with 15 new claims including... 3. The method according to claim 1, wherein the target tissue is selected from the group consisting of brain, scalp, eye, ear, skin, tooth, dental gum, tooth root, sub-mucosa, breast, aorta, limb, artery, heart, heart valve, kidney, pancreas, bladder, liver, joint, bone, and any combination thereof.

2

://https://lnkd.in/giUEBUHC Amprion is proud to be working with ALS Network to elucidate the role of Synuclein co-pathologies in ALS progression. Our previous collaboration with @RichardSmithMD and his Center for Neurologic Studies revealed an ALS co-pathology rate of approximately 14% against an age- and gender-matched control rate of less than 3%. The current follow-on study seeks to determine how Synuclein co-pathology in ALS influences clinical presentation including cognitive effects or enhanced rates of progression. #ALSNetwork #Amprion #CenterForNeurologicStudies #ALSCoPathology #Synuclein

47

2 Comments

NImmune Biopharma, Inc’s Founder, Executive Chairman & CEO Josep B. was recently honored as a Virginia Success Story at THRiVE, Virginia Bio’s largest conference of the year. Dr. Bassaganya-Riera described his role in building a thriving biotech innovation ecosystem from the ground up, encompassing NImmune Biopharma, The NIMML Institute, and BioTherapeutics Inc., alongside Landos Biopharma, Inc., which was recently acquired by AbbVie. He underscored the groundbreaking potential of NImmune’s therapeutics in addressing the unmet clinical needs of millions of patients suffering from autoimmune diseases worldwide. NImmune’s lead drug, omilancor, is a first-in-class, best-in-class, oral, once-daily therapeutic in Phase 3 clinical development with a planned NDA filing for Ulcerative Colitis by 2026 and in Phase 2 clinical development for Crohn’s disease. Additionally, NIM-1324, a first-in-class, oral, once-daily, systemically distributed LANCL2 agonist, is in Phase 2 clinical development for the treatment of systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis and other undisclosed indications. Watch Dr. Bassaganya-Riera’s full remarks below.   #VirginiaBio #THRiVE #PrecisionMedicine #LANCL2

25

3 Comments

Spot-on analysis of Illumina's financial history from startup, with a focus on Jay Flatley's legendary ability to keep a cap on expenses before GRAIL destroyed that discipline. Well worth a read if you're involved in a company that’s finding its way through today's brutal funding environment (or current ILMN management 😥): https://lnkd.in/gAZ6VHbj "Adversity breeds resilience. Just ask Illumina. No, not that Illumina. The OG Illumina led by Jay Flatley." "Recent [Illumina disastrous] history distracts from the blueprint Flatley and the primordial [🤣] team laid down for everyone who followed. Almost no one has paid attention, but biotech's current funding dry spell suggests aspiring entrepreneurs should be taking notes." "Operating efficiency is a lost art in company formation. Despite having a blueprint for over two decades, no other biotech company serving the R&D inputs sector has come close to replicating Illumina's success." "Ginkgo Bioworks, Inc. (founded 2008), 10x Genomics (2012), and Twist Bioscience (2013) were born into an era of easy money. They were built like it, too. PacBio (2004) is spiraling toward bankruptcy, whether investors realize it or not, primarily because it never prioritized operating efficiency in its two-decade history. It shows, too." "If adversity breeds resilience, and resilience breeds profitable operations, then some of the world's most efficient businesses ever created are forming right now during biotech's current funding crunch." [👏👏👏] "We just can't appreciate it yet. We don't even know the names of many of these companies. Some primordial teams are meeting right now, reading this, and about to launch a motherfucker of a business. Good." [👏👏👏]

288

17 Comments

Paul Wallace, the CBO of Constructive Bio, will be at #BIO2024. Talk to him about the transformative power of introducing non-canonical amino acids into biologics and peptides, and discuss how exotic chemistries add value when combined with unprecedented fidelity, specificity, and scalability, as well as our plans for Constructive!

12